Literature DB >> 31486085

TIM-3: An emerging target in the liver diseases.

Lizhen Zhao1, Guoyi Yu2, Qi Han1, Congxian Cui3, Bei Zhang1.   

Abstract

T cell immunoglobulin domain and mucin domain-containing molecule 3 (TIM-3) is found expression in the surface of terminally differentiated T cells and belongs to the TIM family of type Ⅰ transmembrane proteins. It binds to the ligand Galectin-9 and mediates T cell apoptosis. As the research progresses, TIM-3 is also expressed in Th17, NK, monocyte, which binds to ligand and induce immune peripheral tolerance in both mice and man. Numerous researches have demonstrated that TIM-3 influences liver diseases, including liver-associated chronic viral infection, liver fibrosis, liver cancer et al and suggest new approaches to intervention. Currently, targeted therapy of TIM-3 is a new treatment in the field of immunization. Although many studies have proven that TIM-3 has an inhibitory effect in vivo, the specific mechanism is not clear. Herein, we summarize the important role of TIM-3 in the regulation of liver disease and prospects for future clinical research. TIM-3 will provide new targets for improving clinical liver disease.
© 2019 The Scandinavian Foundation for Immunology.

Entities:  

Keywords:  Galectin-9; TIM-3; Th1; autoimmune liver disease; viral hepatitis

Mesh:

Substances:

Year:  2020        PMID: 31486085     DOI: 10.1111/sji.12825

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  Circular RNAs in hepatocellular carcinoma: Recent advances.

Authors:  Zhao-Shan Niu; Wen-Hong Wang
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

2.  Increase in Serum Soluble Tim-3 Level Is Related to the Progression of Diseases After Hepatitis Virus Infection.

Authors:  Lingli Chen; Xiaomei Yu; Chunyan Lv; Yaping Dai; Tao Wang; Shaoxiong Zheng; Yuan Qin; Xiumei Zhou; Yigang Wang; Hao Pei; Hongming Fang; Biao Huang
Journal:  Front Med (Lausanne)       Date:  2022-05-12

Review 3.  Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials.

Authors:  Daniel Compagno; Carolina Tiraboschi; José Daniel Garcia; Yorfer Rondón; Enrique Corapi; Carla Velazquez; Diego José Laderach
Journal:  Biomolecules       Date:  2020-05-12

Review 4.  Modulation of Macrophage Polarization by Viruses: Turning Off/On Host Antiviral Responses.

Authors:  Shaoxiong Yu; Hailiang Ge; Su Li; Hua-Ji Qiu
Journal:  Front Microbiol       Date:  2022-02-11       Impact factor: 5.640

5.  Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection.

Authors:  Jingzhi Yang; Teding Chang; Liangsheng Tang; Hai Deng; Deng Chen; Jialiu Luo; Han Wu; TingXuan Tang; Cong Zhang; Zhenwen Li; Liming Dong; Xiang-Ping Yang; Zhao-Hui Tang
Journal:  Front Immunol       Date:  2022-02-16       Impact factor: 7.561

6.  Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer.

Authors:  S H Petersen; L F Kua; S Nakajima; W P Yong; K Kono
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

7.  TIM-3 Genetic Variants Are Associated with Altered Clinical Outcome and Susceptibility to Gram-Positive Infections in Patients with Sepsis.

Authors:  Caspar Mewes; Tessa Alexander; Benedikt Büttner; José Hinz; Ayelet Alpert; Aron-F Popov; Michael Ghadimi; Tim Beißbarth; Mladen Tzvetkov; Marian Grade; Michael Quintel; Ingo Bergmann; Ashham Mansur
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

Review 8.  Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?

Authors:  Christian Bailly; Xavier Thuru; Bruno Quesnel
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.